Thanks, Rob. morning, Good everyone.
disciplined quarter, Our new growth. and second far $X million eight reflected profitable momentum $XX continued We venture towards funded additional the third we portfolio, quarter transactions to rate million. floating our loan. quality in added an totaling Thus
approach. second underwriting these disciplined experienced quarter loan of our XX.X%, highest million. we exits the as $XX.X yield the and from prepayment the quarter totaling an income maintained achieved accelerated our resulted of loan inception. in yield a portfolio for We XX%, yield in We quarter, during quarterly The events seven portfolio since onboarding our portfolio
by investments funded million was facility. debt our which totaling New addition, joint funded fully Life of In in venture $XX portions our York portfolio two QX,
as add predictable yielding We ATPs, BEC continue portfolio and prepayment the and investments yield reflected warrants. a new where debt opportunities grow our portfolio, stream, in to to income continue leading our we position generates by premium with which industry, maintain a
[ph] with a end the with backlog $XX closed million, line $XX approvals XXXX. $XX loan new We in roughly of quarter million of second quarter first the at committed backlog commitments and of the of in million and a ended
to of continuing June enhance while accelerated us growing was approved backlog and to a opportunities and This XX pipeline and million. backlog robust to million of committed, well NII our $XXX sets income as and companies over Our of awarded XX execute $XX.X and up new prepayment with pipeline committed portfolio income. stream, on
and warrants and we of Powerhouse equity As equity value companies, the with received of the in June XX our of proceeds portfolio with fair our a connection million. TruSignal. in Dynamics warrant positions investment and in termination sale $XX.X of we QX, In XX, held
Subsequent investment QX, totaling to approved and the of backlog at funded At million, momentum providing awarded, end new of committed XXXX. million. portfolio our the with $XX of $X the balance sits to end our one grow July, we us additional for
to was $XX and billion for leaving second of quarter Turning a VC year PitchBook, environment. a of consecutive second the activity, now to the million to in in first venture track still industry over well in companies According VC-backed the down investment quarter capital XXXX, from quarter overall $XXX but approximately strong investing. very invested achieving on
terms in quarter story, of the positioning was In first from was rebounding VC course, The slowest of for quarter. start five-year activity raised the billion in activity second average. VC-backed fundraising the fundraising, and the XXXX big quarter record exit a the XXXX, level to of full-year within $XX in fall of the
the XXXX. in and venture-backed I’ll second billion end Uber, These helped which [ph] by Zoom, IPOs potentially VC returns previously shattering capital, reinvest XX IPOs the to led of allow Pinterest, fundraising $XXX quarterly into value generate record. lead quarter which and in higher VCs XXXX, their the opportunity of lead of to Slack quarter in exit over the second-half with the to and XXXX
to the to life healthcare there show the large high-profile and science IPO by future. continue overall companies, headlines Horizon the this segment strength Importantly, were many dominate IPOs will while over believe sector made comp, continues foreseeable
technology a and financing we now healthcare venture the focused demand funded quarter, loan core markets a remain of markets. pharmaceutical beginning million quarter, market. the $XX on for In to life to in the Turning Dermatology, our dermatology specialty science the Encore strong. At U.S. second company the second
loan one million portfolio portfolio a companies, medical a company, additionally of a our we $X Medical, million venture leading loan We quarter, tech-enabled the our existing develops CSA healthcare science to patent to funded AI during Catasys, devices. $X protected venture Also, publicly-traded funded which and company. existing cryotherapy life
$X on diseases. sector company, genome a Subsequent treat technology funding The to portfolio to LogicBio loan medicines company new new to rare companies. million a we active funded the with continues growth-oriented very to broader developing focused and Therapeutics, venture be specialty editing quarter-end,
venture able to for been to of relationships and to million and BXB that new debt use marketing. meet portfolio $X provided effectively During Demand of on the focused funding and we’ve generally company quarter, our has Solutions remained we a portfolio brand product, as a strong, platform consistently company existing our standards. our tech BridgeX and for compete OutboundEngine, to SaaS million name deals underwriting specifically, $XX.X aggressively
respect to a select Horizon. with the However, – for significant remains focus selectivity tech companies,
requests significant positioned we’re be selective, where the for the technological to are technologies, debt continuing is innovative transactions large opportunities we achieve to seek as advancements. we borrower for Given seeing
the venture in with Overall, investment environment. we’re results pleased our debt
value We continue for exits, new to for and shareholders. many have for our investments opportunities creating
knowledge-based to to win to continue strategy capacity ample while identify to opportunities and long-term our apply and source will well-priced additional our to We ability portfolio attractive pricing our add predictive deliver growth. pipeline, utilizing investments, our
With that, Dan. now the over call to will I turn